Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
SynKinase
CYC116
85
CHF
CHF 85.00
In stock
SYN-1034-M0011 mgCHF 85.00
SYN-1034-M0055 mgCHF 128.00
SYN-1034-M01010 mgCHF 170.00
SYN-1034-M05050 mgCHF 497.00
SYN-1034-M100100 mgCHF 780.00
| Product Details | |
|---|---|
| Synonyms | CYC-116 |
| Product Type | Chemical |
| Properties | |
| Formula | C18H20N6OS |
| MW | 368.5 |
| CAS | 693228-63-6 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO or ethanol. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data |
Target: Aurora A | Kinase Group: Other | Substrate: Serine-Threonine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
| InChi Key | GPSZYOIFQZPWEJ-UHFFFAOYSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
CYC116 is an orally active small molecule multi-kinase inhibitor with anti-neoplastic activity. CYC116 inhibits Aurora kinases A/B and vascular endothelial growth factor receptor 2 (VEGFR2), resulting in disruption of the cell cycle, rapid cell death, and the inhibition of angiogenesis.
Product References
- Discovery and development of aurora kinase inhibitors as anticancer agents: J.R. Pollard & M.J. Mortimore; J. Med. Chem. 52, 2629 (2009)
- Selectivity data: assessment, predictions, concordance, and implications: C. Gao, et al.; J. Med. Chem. 56, 6991 (2013)
Related Products
